Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.58 |
| ▸ | SRC | P12931 | 11/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | BCR | P11274 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497195 | 0.96 | EGFR (0.57) | EGFRERBB2SRCGAKABL1 | |
| SCHEMBL5723525 | 0.92 | SRC (0.62) | EGFRERBB2SRCABL1BCR | |
| SCHEMBL4493118 | 0.92 | SRC (0.59) | EGFRERBB2SRCABL1BCR | |
| SCHEMBL6596134 | 0.91 | SRC (0.58) | EGFRERBB2SRCABL1BCR | |
| Hydrochloric Acid SCHEMBL4496561 | 0.90 | SRC (0.57) | EGFRERBB2SRCABL1BCR | |
| SCHEMBL4489459 | 0.88 | SRC (0.56) | EGFRERBB2SRCABL1BCR | |
| SCHEMBL5724110 | 0.87 | SRC (0.54) | EGFRERBB2SRCABL1BCR | |
| SCHEMBL7130437 | 0.86 | SRC (0.54) | EGFRERBB2SRCGAKABL1 | |
| SCHEMBL5723587 | 0.85 | SRC (0.68) | EGFRERBB2SRCGAKABL1 | |
| SCHEMBL4491501 | 0.85 | SRC (0.56) | EGFRERBB2SRCABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| EP-1409481-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| EP-1409481-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | EGFR 57/4885ERBB2 12/4885SRC 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.